New antibiotics – standstill or progress;Neue Antibiotika – Stillstand oder Fortschritt

Medizinische Klinik - Intensivmedizin und Notfallmedizin

Volumn 112, Issue 3, 2017, Pages 206-213

  Rademacher, J ^a   Welte, T ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Beta lactam resistance; Cephalosporins; Drug resistance, bacterial; Infection; MRSA

Indexed keywords

ANTIBIOTIC AGENT; AVIBACTAM; CEFTAROLINE; CEFTAZIDIME; CEFTOBIPROLE; CEFTOLOZANE; LINEZOLID; MACROLIDE; OXAZOLIDINONE DERIVATIVE; SOLITHROMYCIN; TAZOBACTAM; TEDIZOLID; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; EPHEDRINE; EPHEDRINE, PHENOBARBITAL, THEOPHYLLINE DRUG COMBINATION; ORGANOPHOSPHATE; OXAZOLE DERIVATIVE; PENICILLANIC ACID; PHENOBARBITAL; THEOPHYLLINE; TRIAZOLE DERIVATIVE;

ARTICLE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; ANALOGS AND DERIVATIVES; BACTERIAL INFECTION; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DRUG APPROVAL; DRUG COMBINATION; DRUG EFFECTS; HUMAN; MULTIDRUG RESISTANCE; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTERIAL INFECTIONS; CEFTAZIDIME; CEPHALOSPORINS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EPHEDRINE; HUMANS; MACROLIDES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; ORGANOPHOSPHATES; OXAZOLES; PENICILLANIC ACID; PHENOBARBITAL; STAPHYLOCOCCAL INFECTIONS; THEOPHYLLINE; TRIAZOLES;

EID: 85027931887     PISSN: 21936218     EISSN: 21936226     Source Type: Journal    
DOI: 10.1007/s00063-017-0271-3     Document Type: Article

References (16)

1. Awad SS, Rodriguez AH, Chuang YC, Marjanek Z, Pareigis AJ, Reis G, Scheeren TW, Sánchez AS, Zhou X, Saulay M, Engelhardt M (2014) A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis 59(1):51–61
2. Zhong NS, Sun T, Zhuo C et al (2015) Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial. Lancet Infect Dis 15(2):161–171
3. Oldach D, Clark K, Schranz J et al (2013) Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia. Antimicrob Agents Chemother 57(6):2526–2534
4. Wunderink RG, Niederman MS, Kollef MH et al (2012) Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 54(5):621–629
5. Brinker AD, Wassel RT, Lyndly J, Serrano J, Avigan M, Lee WM, Seeff LB (2009) Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology 49(1):250–257
6. Chastre J, Blasi F, Masterton RG et al (2014) European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid. Clin Microbiol Infect 20(Suppl 4):19–36
7. Prokocimer P, De Anda C, Fang E et al (2013) Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 309(6):559–569
8. Moran GJ, Fang E, Corey GR et al (2014) Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 14(8):696–705
9. Gastmeier P, Schröder C et al (2014) Dramatic increase in vancomycin-resistant enterococci in Germany. J Antimicrob Chemother 69(6):1660–1664
10. Solomkin J, Hershberger E, Miller B et al (2015) Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI). Clin Infect Dis 60(10):1462–1471
11. Wagenlehner FM, Umeh O, Steenbergen J et al (2015) Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 385(9981):1949–1956
12. Lucasti C, Popescu I, Ramesh MK et al (2013) Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial. J Antimicrob Chemother 68(5):1183–1192
13. Mazuski JE, Gasink LB, Armstrong J et al (2016) Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis 62(11):1380–1389
14. Vazquez JA, González Patzán LD et al (2012) Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin 28(12):1921–1931
15. Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, Gasink LB (2016) Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis 16(6):661–673
16. European Centre for Disease Prevention and Control (2015) Annual epidemiological report 2014. Antimicrobial resistance and healthcare-associated infections. ECDC, Stockholm (http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-annual-epidemiological-report.pdf)